Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BQ65
UPID:
USB1_HUMAN
Alternative names:
3'-5' RNA exonuclease USB1; Mutated in poikiloderma with neutropenia protein 1
Alternative UPACC:
Q9BQ65; B4DWE3; B4DZW5; Q96FZ9; Q9H8X8
Background:
U6 snRNA phosphodiesterase 1, also known as 3'-5' RNA exonuclease USB1, plays a crucial role in RNA processing. It trims the 3' end of oligo(U) and oligo(A) tracts of pre-U6 small nuclear RNA (snRNA), leading to mature U6 snRNA formation. This protein is essential for U6 snRNA 3' end processing, preventing its degradation and ensuring the stability of RNA molecules involved in critical cellular functions.
Therapeutic significance:
Given its pivotal role in RNA processing and stability, U6 snRNA phosphodiesterase 1 is linked to Poikiloderma with neutropenia, a genodermatosis characterized by skin abnormalities and increased susceptibility to infections. Understanding the role of U6 snRNA phosphodiesterase 1 could open doors to potential therapeutic strategies for treating this disorder and possibly other RNA-related diseases.